Capsular serotype in group b streptococcus colonization and disease - despite ongoing surveillance and control efforts, group b streptococcus (GBS) remains an important cause of infectious morbidity…

Ended Project Grant Awarded Last action

Award ID
R01AI155476
Recipient
Awarding agency
Obligated
$7,028,709

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Funding
  • $6,318,465.00 Federal
  • $710,244.00 Non-federal
Place of performance
New York, NY 10016, USA

Award details come from USAspending.gov.

Description

Capsular serotype in group b streptococcus colonization and disease - despite ongoing surveillance and control efforts, group b streptococcus (GBS) remains an important cause of infectious morbidity and mortality among newborns, as well as an increasing cause of invasive disease in adults. GBS vaccine development is a high priority, and a candidate conjugate polysaccharide vaccine is currently in human trials. This vaccine targets six of the ten known GBS serotypes, based on epidemiologic studies of invasive disease as well as rectovaginal carriage. Serotype distribution data are largely based on assays of single colonies from clinical samples. Based on our preliminary data, we hypothesize that carriage of non- vaccine type (NVT) GBS (serotypes VI-IX) is substantially more common than previously realized. Additionally, invasive infections due to NVT GBS are increasing in frequency. IT is not known whether the less common GBS serotypes are intrinsically less fit than the more common ones with respect to colonization efficiency or pathogenicity. Likewise, the importance of recently characterized naturally occurring "capsule switch" GBS strains, in which the genetic locus that determines capsular type has transferred from one strain to another, remains incompletely understood. Here we propose a program of research designed to test hypotheses regarding the prevalence of (and risk factors for) colonization and invasive infection due to NVT GBS serotypes in human samples and to use newly developed techniques for GBS genome manipulation to understand the role of specific capsule and non-capsule factors in colonization fitness and pathogenesis in vivo.

Transactions

Action Federal Non-federal Date
Amendment $695,959 $0
Amendment $695,959 $0
Amendment $695,959 $0
Amendment $702,525 $0
Amendment $702,525 $0
Amendment $702,525 $0
Amendment $702,525 $0
Amendment $710,244 $0
Original award $710,244 $710,244

Subawards

Subrecipient Amount Awarded
University Of Maryland Capsular serotype in group B Streptococcus colonization and disease $80,993
University Of Maryland $80,993
University Of Maryland Baltimore County $87,559
University Of Maryland Baltimore County $87,559

Quick answers

Who received award R01AI155476?

R01AI155476 was awarded to New York University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 8, 2021.

How much is award R01AI155476 worth?

$7,028,709 has been obligated on R01AI155476: $6,318,465 in federal funding and $710,244 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award